Turbogen Narrows Net Loss to $4.2 Million in H1 2026 Amid Nasdaq Plans

Turbogen has released its financial results for the six-month period ending June 30, 2026, highlighting significant progress toward its commercialization strategy and Nasdaq listing.

R&D and Operating Expenses

According to the data, research and development expenses rose to $1.9 million, compared to $0.6 million in the corresponding period in 2025. This increase was driven by broader operational scale, materials and subcontractor costs, preparations for large-scale production, and share-based payments. General and administrative expenses increased to $3.1 million, up from $1.4 million in the same period in 2025, largely due to growth in share-based payments and professional expenses related to the Nasdaq registration process. Consequently, the operating loss widened to $5.2 million, compared to $2.3 million in the parallel period last year.

Net Loss and Cash Flow Improvement

Despite higher operating expenses, the net loss narrowed by 45% to $4.2 million, compared to $7.6 million in the first half of 2025. This improvement stemmed primarily from a positive change of $6.4 million in the fair value of warrants and debt settlement effects, partially offset by rising operational costs. Cash and cash equivalents totaled $7.2 million as of June 30, 2026, compared to $3.9 million at the end of December 2025. Net cash used in operating activities reached $2.7 million, while equity turned positive at $1.6 million.

"Our robust cash balance, combined with the $5 million we raised in August, supports our preparations for commercialization. The Nasdaq listing is a significant milestone for us, and we expect it to expand our exposure to US investors as we advance our commercial strategy," said Yaron Gilboa, CEO of Turbogen.